President Donald Trump has directed federal agencies to expand access to certain psychedelic substances for therapeutic use, according to multiple reports citing administration officials. The directive, which emerged in early 2025, focuses on compounds such as psilocybin, LSD, and ibogaine, particularly for veterans suffering from post-traumatic stress disorder and treatment-resistant depression. While the administration has not released the full text of any executive order, sources indicate the move aims to accelerate research and reduce regulatory barriers under existing federal frameworks.
The initiative reflects a growing bipartisan interest in psychedelic-assisted therapy, driven by clinical trials showing promising results for mental health conditions. However, the substances involved remain classified as Schedule I drugs under the Controlled Substances Act, meaning they are considered to have a high potential for abuse and no accepted medical use under federal law. Any expansion of access would require coordination between the Food and Drug Administration, the Drug Enforcement Administration, and the Department of Veterans Affairs, though no formal interagency plan has been made public.
Advocacy groups have long urged the federal government to reconsider restrictions on psychedelics, citing evidence from studies conducted in controlled settings. Researchers at institutions like Johns Hopkins University and Imperial College London have demonstrated that psilocybin, when administered with psychotherapy, can produce significant and lasting reductions in depression and anxiety. Similarly, ibogaine has been used in informal settings abroad to treat opioid dependence, though its use carries cardiac risks and is not approved in the United States.
Despite these findings, federal regulators have maintained a cautious stance. The FDA has granted breakthrough therapy designation to psilocybin-assisted treatment for major depressive disorder, a status intended to expedite development and review. Yet, as of early 2025, no psychedelic substance has received full FDA approval for any medical indication. The agency continues to emphasize that clinical trials must adhere to rigorous standards to establish safety and efficacy.
Administrative Actions and Regulatory Pathways
Reports suggest the administration’s directive instructs federal agencies to explore pathways for expanded access, including potential rescheduling or the creation of special access programs for veterans. The Department of Veterans Affairs has previously authorized limited use of complementary therapies, such as acupuncture and yoga, but has not permitted psychedelics in clinical settings due to their legal status and safety profile.
Any attempt to reschedule a substance would require a formal review by the Department of Health and Human Services and the DEA, a process that can take years and involves scientific evaluation of abuse potential, medical utility, and safety. Alternatively, the administration could pursue regulatory guidance that clarifies existing exceptions, such as those for investigational new drug applications or expanded access programs for patients with life-threatening conditions.
To date, no official document has been published in the Federal Register outlining the specifics of the directive. White House officials have not responded to requests for comment, and the Department of Justice has not issued any public statement regarding enforcement priorities related to psychedelics under the new guidance.
Scientific Context and Clinical Evidence
Modern research into psychedelics has expanded significantly since the early 2000s, following decades of restriction after the substances were criminalized in the late 1960s. Clinical trials have primarily focused on psilocybin for depression and anxiety, MDMA for post-traumatic stress disorder, and ibogaine for substance use disorders. While MDMA is not included in the reported directive, it has advanced further in the approval process, with Phase III trials completed and a new drug application under review by the FDA.
Studies involving psilocybin have shown that a single or double dose, combined with psychological support, can lead to rapid and sustained improvements in mood. A 2021 study published in JAMA Psychiatry found that psilocybin-assisted therapy produced greater reduction in depressive symptoms than placebo over a four-week period. However, researchers caution that these results are based on highly controlled environments and may not reflect real-world use.
Ibogaine, derived from a West African shrub, has been used in informal clinics in countries like Mexico and New Zealand to interrupt opioid addiction. Its mechanism is not fully understood, but it appears to interrupt withdrawal symptoms and reduce cravings. However, ibogaine can cause serious cardiac complications, including arrhythmias, and has been associated with fatalities in unsupervised settings. The drug is not currently under investigation for FDA approval in the United States.
Veterans and Mental Health Advocacy
Veteran advocacy groups have been particularly vocal in pushing for access to psychedelic therapies, citing high rates of PTSD, depression, and suicide among former service members. According to the Department of Veterans Affairs, approximately 12% of veterans who served in Operations Iraqi Freedom and Enduring Freedom experience PTSD in a given year. Traditional treatments, including selective serotonin reuptake inhibitors and trauma-focused psychotherapy, are effective for many but do not work for everyone.
Organizations such as Heroic Hearts Project and VETS, Inc. Have facilitated trips abroad for veterans seeking ibogaine or psilocybin treatments, operating in legal gray areas. These groups argue that current federal restrictions prevent access to potentially life-saving options and call for clinical trials to be conducted within the VA system.
The VA has stated that it supports research into innovative treatments but must comply with federal law. In 2023, the department announced a partnership with Johns Hopkins to study the effects of psilocybin on depression in veterans, though the study had not begun enrollment as of early 2025 due to regulatory delays.
Legal and Political Considerations
The push for psychedelic reform has gained traction across the political spectrum. Several states and cities have taken steps to decriminalize or deprioritize enforcement of laws against natural psychedelics. Oregon became the first state to legalize psilocybin for therapeutic use in 2020, establishing a regulated service model. Colorado followed in 2022, and similar measures have appeared in local ballots in California and Massachusetts.
At the federal level, lawmakers from both parties have introduced bills to facilitate research. The Veterans Equal Access Act, which would allow VA doctors to recommend medical marijuana in states where it is legal, has been cited as a model for potential psychedelic reform. However, no equivalent legislation has advanced for psychedelics.
Any expansion of access under the current administration would likely face scrutiny from public health officials and lawmakers concerned about potential misuse. Critics note that while therapeutic use in controlled settings shows promise, broader availability could increase risks of adverse psychological reactions, particularly in individuals with a history of psychosis.
Next Steps and Outlook
As of mid-2025, no formal policy changes have been implemented, and the administration has not issued additional guidance on the directive. The next expected step is a potential update from the Office of National Drug Control Policy or a formal notice in the Federal Register outlining specific actions. Researchers and advocacy groups continue to call for transparency and evidence-based policymaking.
For individuals seeking information on clinical trials involving psychedelics, the National Institutes of Health maintains a searchable database at clinicaltrials.gov, where studies can be filtered by condition, intervention, and location. The FDA also provides guidance on expanded access pathways for investigational drugs through its official website.
Until federal policy shifts, the use of psilocybin, LSD, and ibogaine remains illegal outside of approved research settings. Those considering such treatments are advised to consult healthcare providers and participate only in legally sanctioned trials to ensure safety and proper medical oversight.
We invite readers to share their perspectives on this developing topic in the comments below and to share this article with others interested in mental health policy and scientific innovation.